Skip to content

Intravenous Immunoglobulins for Post-Polio Syndrome

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01537575
Enrollment
50
Registered
2012-02-23
Start date
2008-01-31
Completion date
Unknown
Last updated
2012-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-polio Syndrome

Brief summary

Postpolio syndrome is a condition that affects many polio survivors years after the acute infection and causes symptoms to increase or new symptoms to develop. Proinflammatory cytokine production within the central nervous system (CNS) indicates an underlying inflammatory process, amenable to immunomodulatory therapy. In this study the investigators sought to confirm that antiinflammatory treatment with intravenous immunoglobulin improves the disease.

Interventions

One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days

BIOLOGICALSaline solution

Placebo

Sponsors

Azienda Ospedaliera Universitaria Integrata Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* a history of acute poliomyelitis * increased muscle weakness, muscle fatigue and pain in muscle groups previously affected by poliomyelitis * a diagnosis of postpolio syndrome according to the criteria of Halstead and Rossi

Exclusion criteria

* clinically relevant systemic disease * malignancy * hypothyroidism * diabetes mellitus not fully controlled by medical therapy * medical or orthopedic disorders that could give rise to symptoms mimicking post-polio syndrome * conditions associated with prolonged coagulation time * serum IgA deficiency * previous allergic reaction to IVIG * body-mass index greater than 30 * immune-modulating treatments other than IVIG within the preceding 6 months

Design outcomes

Primary

MeasureTime frame
SF-36 physical componentBaseline; 2 and 4 months after treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026